Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

Inclusion criteria * Patient completed Omnibus study and will be available to immediately rollover into this study without discontinuation of study drug. * Patient was not discontinued from the previous Omnibus study. * Male or female, adult patients with CHB (HBeAg positive or HBeAg negative). * Patient is willing and able to provide written informed consent to participate in the study. * HBV DNA PCR undetectable in recent 12 months. Exclusion criteria * Pregnant or breastfeeding, or has plan of pregnant during study period. * Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), r HIV at screening visit. * Patient needs any anti-HBV treatment combination (add-on therapy) or switch to other anti HBV treatment from Telbivudine at investigator's discretion. * Patient has any laboratory value abnormality that physicians think he/she may not be suitable to continue the Telbivudine treatment. * Patient has any clinically significant concurrent severe or unstable disease conditions that physicians think he/she may have any additional risk or not be suitable to participate the study. * Patient has evidence of renal insufficiency defined as patient requiring dialysis or having an estimated creatinine clearance below 50mL/min, as estimated by the cockcroft-Gault formula. * Patient is currently abusing alcohol or illicit drugs. * Patient is enrolled or plans to enroll in another clinical trial of an investigational agent while participating in this study. * All other treatments for hepatitis B, including commercially available treatments indicated for conditions other than chronic hepatitis B that are being investigated to treat or may have activity against HBV (e.g., ribavirin, famciclovir, ganciclovir, etc.) * Prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with these agents for periods exceeding 10 days every 3 months, or chronic suppressive therapy. * Systemic immunomodulators of any type. * Systemic corticosteroids ( topical and inhaled corticosteroids are permitted). * Herbal medications known to cause hepatotoxicity (e.g., St. John's Wart, Kava, Jin Bu Huan, Yuzhitang, germander, chaparral, shark cartilage, mistletoe, slim 10, Lipokinetix, etc.). * Patient has any of the following laboratory values: * Hemoglobin \< 9 g/dL for menor \<8 g/dL for women. * Total WBC \<1,500/mm3 * Absolute neutrophil count (ANC)\<1,000/mm3 * Platelet count \<30,000/mm3 * Serum albumin \<2.5g/dL * Total bilirubin ≥4×ULN * Serum creatinine \>1.5×ULN